Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma

The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both preclinical and clinical testing, necessitating...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldwin, Paige, Likhotvorik, Rostislav, Baig, Nabeela, Cropper, Jodie, Carlson, Ruth, Kurmasheva, Raushan, Sridhar, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928193/
https://www.ncbi.nlm.nih.gov/pubmed/31921673
http://dx.doi.org/10.3389/fonc.2019.01416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928193/
https://www.ncbi.nlm.nih.gov/pubmed/31921673
http://dx.doi.org/10.3389/fonc.2019.01416

Ejemplares similares